Figure 2.

Anti-CD4 antibody coated nlg- KN93 suppresses EAE. (A) (Prevention study) Average clinical score of the mice treated with nlg- empty, anti CD4 antibody coated nlg- empty (CD4− nlg- empty), nlg- KN-93 (4 μg/week) and CD4− nlg- KN-93 (4 μg/week) after immunization with MOG_35-55 in CFA (n = 8 mice in each group). The nlg were injected into the peritoneum weekly from day 0. **P<0.01 by 2way ANOVA. Mice were monitored daily and clinical scores were given as follows: 1, limp tail; 2, hind-limb paresis; 3, hind-limb paralysis; 4, tetraplegia; 5, moribund. (B - D) Intracellular staining of IFN-γ and IL-17A in spinal cord- derived cells from the treated mice 14 days after immunization or the normal B6 mice (no EAE) for negative control. Absolute cell numbers of whole infiltrating cells (B), IL-17A (C) and IFN-γ producing CD4⁺ T cells (D) in spinal cord in each treatment group. (E) Spinal cord sections from each treated mouse was obtained at 14 days after immunization. Sections were stained with luxol fast blue to assess inflammation and myelin content. Each scale bar represents 100 μm. Data are representative of 3 independent experiments. (F) Quantitative data of histological score. (B - D, F) Each Symbol represents an independent experiment. Error bars represent the mean ± SEM. *P < 0.05, **P<0.01 by 1way ANOVA with Bonferroni’s post-test. (G) Average clinical score of mice treated with CD4− nlg- KN-93 (10 μg / week) or control nlg from day 12 after immunization (n = 10 mice in each group). The nlg were injected weekly from day 12. *P<0.05 by 2way ANOVA with Bonferroni’s post-test.